Five things to know:
1. Zolgensma was developed by AveXis, a biotechnology company acquired by Novartis for $8.7 billion in 2018.
2. The drugs is priced at $2.1 million and offers a one-time treatment for the rare neurological disease.
3. About 400 patients have been treated with Zolgensma so far.
4. Fifteen to 20 SMA patients in Japan are expected to be eligible for treatment annually.
5. Novartis is pursuing registration in more than 30 countries, with regulatory decisions anticipated in Switzerland, Canada and Australia in late 2020 or early 2021.
More articles on biologics:
NuVasive recalls Magec system for scoliosis, advises surgeons to perform clinical follow-ups
Zimmer Biomet asks European hospitals to remove orthopedic spacer molds
Resurgens Orthopaedics postpones elective surgeries, remains open for urgent care
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
